US FDA grants marketing authorization to Fujirebio Diagnostics Lumipulse G

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., announced that the US Food and Drug Administration (FDA) has granted De Novo marketing authorization for the company